跳转至内容
Merck

R0900000

Rifamycin B

European Pharmacopoeia (EP) Reference Standard

别名:

Rifamycin impurity A

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C39H49NO14
CAS号:
分子量:
755.80
Beilstein:
604953
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

rifamycin, rifampicin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

N1c2c(c3c(c4c(c(c3O)C)O[C@](O\C=C\[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](\C=C\C=C(/C1=O)\C)C)O)C)O)C)OC(=O)C)C)OC)(C4=O)C)c(c2)OCC(=O)O)O

InChI

1S/C39H49NO14/c1-17-11-10-12-18(2)38(49)40-24-15-26(51-16-27(42)43)28-29(34(24)47)33(46)22(6)36-30(28)37(48)39(8,54-36)52-14-13-25(50-9)19(3)35(53-23(7)41)21(5)32(45)20(4)31(17)44/h10-15,17,19-21,25,31-32,35,44-47H,16H2,1-9H3,(H,40,49)(H,42,43)/b11-10+,14-13+,18-12-/t17-,19+,20+,21+,25-,31-,32+,35+,39-/m0/s1

InChI 密鑰

SQTCRTQCPJICLD-KTQDUKAHSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Rifamycin B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Zhi-Hua Jin et al.
Journal of Zhejiang University. Science, 5(12), 1590-1596 (2004-11-18)
Study of the effect of dissolved oxygen and shear stress on rifamycin B fermentation with A. mediterranei XC 9-25 showed that rifamycin B fermentation with Amycolatoposis mediterranei XC 9-25 needs high dissolved oxygen and is not very sensitive to shearing
Zhi Hua Jin et al.
The Journal of general and applied microbiology, 48(6), 329-334 (2003-04-12)
An industrially applied rifamycin B-producing strain, Amycolatopsis mediterranei XC 1-02, was used for further screening. A special mutation and screening procedure was adopted to select a strain, which can alleviate the inhibition caused by both aromatic amino acid and p-hydroxybenzoic
Jun Xu et al.
Archives of biochemistry and biophysics, 411(2), 277-288 (2003-03-08)
The gene rif orf14 in the rifamycin biosynthetic gene cluster of Amycolatopsis mediterranei S699, producer of the antitubercular drug rifamycin B, encodes a protein of 272 amino acids identified as an AdoMet: 27-O-demethylrifamycin SV methyltransferase. Frameshift inactivation of rif orf14
Xuan-Tien Doan et al.
Journal of biotechnology, 132(2), 156-166 (2007-08-04)
Industrial production of antibiotics, biopharmaceuticals and enzymes is typically carried out via a batch or fed-batch fermentation process. These processes go through various phases based on sequential substrate uptake, growth and product formation, which require monitoring due to the potential
Prashant M Bapat et al.
Applied microbiology and biotechnology, 72(4), 662-670 (2006-03-15)
It is well-known that secondary metabolite production is repressed by excess nitrogen substrate available in the fermentation media. Although the nitrogen catabolite repression has been known, quantitative process models have not been reported to represent this phenomenon in complex medium.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门